Delivery Order SPE2DR25D2206-SPE2DR26F9CV4
- Not listed
- The Defense Logistics Agency awarded a $12,994.64 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on December 8, 2025, with completion targeted for December 30, 2025. This is a firm fixed price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, leveraging the company's extensive capabilities as a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,165.34 and an ultimate completion date of June 24, 2025. The contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector pharmaceutical product, valued at $9,975.58, with a firm fixed price structure. This delivery order, issued on May 6, 2025, is classified as a child contract under a larger vehicle and carries an ultimate completion date of May 28, 2025. The award represents a non-competitive delivery order executed under AmerisourceBergen's existing indefinite delivery contract framework...
- The Defense Logistics Agency awarded a delivery order valued at $9,745.98 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on December 11, 2025. This non-competitive delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on December 9, 2025, with completion expected by December 31, 2025. This competitively awarded, firm fixed-price delivery order requires performance at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $12,330.68 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical supply. The contract, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $6,497.32 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Benlysta 200 mg/ml auto-injector medication. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 12, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This is a firm fixed price contract with an ultimate completion date of August 14, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was competitively awarded....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 MG/ML auto-injector supplies, with a ceiling value of $3,082.67. This non-competitive delivery order, issued on October 28, 2025, carries a completion deadline of November 19, 2025. The award employs firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply relationship. Performance will be executed from the company's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injector on November 20, 2025, with an ultimate completion date of December 12, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9CV4Delivery Order
The Defense Logistics Agency awarded a $12,994.64 delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector medication. This is a firm fixed price, competitively awarded contract with an ultimate completion date of December 16, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a prime contractor for the Defense Logistics Agency's Medical Supply Chain, fulfilling critical pharmaceutical needs for military and federal healthcare systems. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical support vehicle, which enables the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally. Benlysta (belimumab) is a biologic immunosuppressant used primarily in the treatment of systemic lupus erythematosus and other autoimmune conditions, representing the type of specialized therapeutic medication that supports Defense Health Agency and military beneficiary healthcare requirements. The contract carries no set-aside designation, confirming that AmerisourceBergen competed for this award through open competition, consistent with its established pattern of competitively awarded federal contracts across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 11/23/25 |